Unknown

Dataset Information

0

Repurposing diflunisal for familial amyloid polyneuropathy: a randomized clinical trial.


ABSTRACT: Familial amyloid polyneuropathy, a lethal genetic disease caused by aggregation of variant transthyretin, induces progressive peripheral nerve deficits and disability. Diflunisal, a nonsteroidal anti-inflammatory agent, stabilizes transthyretin tetramers and prevents amyloid fibril formation in vitro.To determine the effect of diflunisal on polyneuropathy progression in patients with familial amyloid polyneuropathy.International randomized, double-blind, placebo-controlled study conducted among 130 patients with familial amyloid polyneuropathy exhibiting clinically detectable peripheral or autonomic neuropathy at amyloid centers in Sweden (Umeå), Italy (Pavia), Japan (Matsumoto and Kumamoto), England (London), and the United States (Boston, Massachusetts; New York, New York; and Rochester, Minnesota) from 2006 through 2012.Participants were randomly assigned to receive diflunisal, 250 mg (n=64), or placebo (n=66) twice daily for 2 years.The primary end point, the difference in polyneuropathy progression between treatments, was measured by the Neuropathy Impairment Score plus 7 nerve tests (NIS+7) which ranges from 0 (no neurological deficits) to 270 points (no detectable peripheral nerve function). Secondary outcomes included a quality-of-life questionnaire (36-Item Short-Form Health Survey [SF-36]) and modified body mass index. Because of attrition, we used likelihood-based modeling and multiple imputation analysis of baseline to 2-year data.By multiple imputation, the NIS+7 score increased by 25.0 (95% CI, 18.4-31.6) points in the placebo group and by 8.7 (95% CI, 3.3-14.1) points in the diflunisal group, a difference of 16.3 points (95% CI, 8.1-24.5 points; P?

SUBMITTER: Berk JL 

PROVIDER: S-EPMC4139164 | biostudies-literature | 2013 Dec

REPOSITORIES: biostudies-literature

altmetric image

Publications


<h4>Importance</h4>Familial amyloid polyneuropathy, a lethal genetic disease caused by aggregation of variant transthyretin, induces progressive peripheral nerve deficits and disability. Diflunisal, a nonsteroidal anti-inflammatory agent, stabilizes transthyretin tetramers and prevents amyloid fibril formation in vitro.<h4>Objective</h4>To determine the effect of diflunisal on polyneuropathy progression in patients with familial amyloid polyneuropathy.<h4>Design, setting, and participants</h4>In  ...[more]

Similar Datasets

| S-EPMC4098875 | biostudies-literature
| S-EPMC7583827 | biostudies-literature
| S-EPMC7170468 | biostudies-literature
| S-EPMC6599258 | biostudies-literature
| S-EPMC6116977 | biostudies-literature
| S-EPMC4788142 | biostudies-other
| S-EPMC5853640 | biostudies-literature
| S-EPMC5288465 | biostudies-literature
| S-EPMC4739312 | biostudies-literature
| S-EPMC3825212 | biostudies-literature